Home » FDA Awards Stealth BioTherapeutics Fast Track for MTP-131
FDA Awards Stealth BioTherapeutics Fast Track for MTP-131
Stealth BioTherapeutics has scooped up FDA fast track designation for its MTP-131 — also known as Bendavia — for the treatment of primary mitochondrial myopathy.
MTP-131 fights the disease by targeting the inner mitochondrial membrane.
The drug is currently in a Phase 1/2 trial with results expected midyear, the Newton, Mass.-based company says.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May